Search Clinical Trials
598,193 trials
ID
Status
Phase
Title
Sponsor
NCT07763171
Paclitaxel, Ramucirumab and Tislelizumab Switch Maintenance in Advanced HER2-negative and PD-L1 TAP Score of 5 or More Advanced Gastroesophageal AdenocarcinomaGruppo Oncologico del Nord-OvestNot Yet RecruitingPhase 3
NCT07763171Not Yet Recruiting
Phase 3
Paclitaxel, Ramucirumab and Tislelizumab Switch Maintenance in Advanced HER2-neg...Gruppo Oncologico del Nor...
NCT07762482
Periodontal Tissue Stability After Surgical Correction of Altered Passive EruptionUniversity of Sao PauloRecruitingNot Applicable
NCT07762482Recruiting
Not Applicable
Periodontal Tissue Stability After Surgical Correction of Altered Passive Erupti...University of Sao Paulo
NCT07764107
Photobiomodulation for Reducing Sedative-Hypnotic Use:Clinical Trial of a Light-Therapy DeviceNational Health Research Institutes, TaiwanNot Yet RecruitingNot Applicable
NCT07764107Not Yet Recruiting
Not Applicable
Photobiomodulation for Reducing Sedative-Hypnotic Use:Clinical Trial of a Light-...National Health Research...
NCT07763067
Acceptability and Outcomes of an Online Parent-Mediated Intervention for Young Autistic ChildrenHerguner Therapy Private ClinicCompletedNot Applicable
NCT07763067Completed
Not Applicable
Acceptability and Outcomes of an Online Parent-Mediated Intervention for Young A...Herguner Therapy Private...
NCT07762703
Combination Immunotherapy Treatment for Locally Advanced Unresectable or Metastatic, PD-L1 Negative (CPS<10), gBRCA Negative, Triple Negative Breast Cancer Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 TherapyBreakBio CorpNot Yet RecruitingPhase 1
NCT07762703Not Yet Recruiting
Phase 1
Combination Immunotherapy Treatment for Locally Advanced Unresectable or Metasta...BreakBio Corp
NCT07764341
Supervised Exercise During Neoadjuvant Chemotherapy for Breast CancerBahrain Oncology CenterNot Yet RecruitingNot Applicable
NCT07764341Not Yet Recruiting
Not Applicable
Supervised Exercise During Neoadjuvant Chemotherapy for Breast CancerBahrain Oncology Center
NCT07764146
An Open Label Dose Escalation Study of VY1706 in Participants With Early Alzheimer's DiseaseVoyager TherapeuticsNot Yet RecruitingPhase 1
NCT07764146Not Yet Recruiting
Phase 1
An Open Label Dose Escalation Study of VY1706 in Participants With Early Alzheim...Voyager Therapeutics
NCT07763379
THE ROLE OF C-REACTIVE PROTEIN (CRP) IN THE EARLY DIAGNOSIS OF ANASTOMOTIC LEAKAGE FOLLOWING PRIMARY REPAIR IN GASTROINTESTINAL SURGERYSohag UniversityRecruiting
NCT07763379Recruiting
—
THE ROLE OF C-REACTIVE PROTEIN (CRP) IN THE EARLY DIAGNOSIS OF ANASTOMOTIC LEAKA...Sohag University
NCT07762248
Impact of Minimally Invasive Endodontic Treatment on the Prognosis of Mandibular Permanent Molars With Necrotic Pulp and Apical PeriodontitisMohamed Ashraf AbdeenNot Yet RecruitingPhase 2
NCT07762248Not Yet Recruiting
Phase 2
Impact of Minimally Invasive Endodontic Treatment on the Prognosis of Mandibular...Mohamed Ashraf Abdeen
NCT07762599
Silver Nanoparticle-Reinforced Double Antibiotic Paste in Symptomatic Apical Periodontitis: A Randomized Controlled TrialAll India Institute of Medical SciencesNot Yet RecruitingNot Applicable
NCT07762599Not Yet Recruiting
Not Applicable
Silver Nanoparticle-Reinforced Double Antibiotic Paste in Symptomatic Apical Per...All India Institute of Me...
NCT07762573
Dynamic Functional Imaging Phenotyping and Disease Progression Risk Assessment in COPD Using Dynamic Chest Radiography: A Multicenter Retrospective StudyNanfang Hospital, Southern Medical UniversityRecruiting
NCT07762573Recruiting
—
Dynamic Functional Imaging Phenotyping and Disease Progression Risk Assessment i...Nanfang Hospital, Souther...
NCT07762755
Icosapent Ethyl for High-Risk Coronary Plaques Assessed by 18F-NaF PET/CTBeijing Anzhen HospitalNot Yet RecruitingPhase 4
NCT07762755Not Yet Recruiting
Phase 4
Icosapent Ethyl for High-Risk Coronary Plaques Assessed by 18F-NaF PET/CTBeijing Anzhen Hospital
NCT07762014
rBCG-N-RSV Vaccine in Adults Aged 60 Years and OlderBiothervax SpANot Yet RecruitingPhase 2
NCT07762014Not Yet Recruiting
Phase 2
rBCG-N-RSV Vaccine in Adults Aged 60 Years and OlderBiothervax SpA
NCT07763613
Clinical Evaluation of the Pelvic Floor Fatigue Index (PFFI)Trabzon Kanuni Education and Research HospitalNot Yet Recruiting
NCT07763613Not Yet Recruiting
—
Clinical Evaluation of the Pelvic Floor Fatigue Index (PFFI)Trabzon Kanuni Education...
NCT07763730
Effects of Robotic Pet and Video-Based Distraction on Pain, Fear, and Anxiety in Children During VenipunctureAkdeniz UniversityCompletedNot Applicable
NCT07763730Completed
Not Applicable
Effects of Robotic Pet and Video-Based Distraction on Pain, Fear, and Anxiety in...Akdeniz University
NCT07763951
Clinical Study to Determine Bioequivalence Between Two Oral Medications of Sitagliptin/Metformin in Prolonged-release Tablets With 100 mg/1000 mg in Healthy Subjects, Fast Study.ADIUMCompletedNot Applicable
NCT07763951Completed
Not Applicable
Clinical Study to Determine Bioequivalence Between Two Oral Medications of Sitag...ADIUM
NCT07763301
YMN-136 Vaccine for Patients With Advanced Hepatobiliary and Pancreatic MalignanciesWest China HospitalRecruitingPhase 1
NCT07763301Recruiting
Phase 1
YMN-136 Vaccine for Patients With Advanced Hepatobiliary and Pancreatic Malignan...West China Hospital
NCT07763795
Effects of BFRT on Glycemic Control, Nerve Conduction, Functional Outcomes and QOL in Individuals With Type 2 DiabetesSuperior UniversityActive Not RecruitingNot Applicable
NCT07763795Active Not Recruiting
Not Applicable
Effects of BFRT on Glycemic Control, Nerve Conduction, Functional Outcomes and Q...Superior University
NCT07764042
Effects of Wet Cupping Therapy in Patients With AsthmaMedipol UniversityCompletedNot Applicable
NCT07764042Completed
Not Applicable
Effects of Wet Cupping Therapy in Patients With AsthmaMedipol University
Result Breakdown
Not yet recruiting10 (50%)
Recruiting5 (25%)
Completed4 (20%)
Active, not recruiting1 (5%)
not_applicable9 (45%)
Not Specified4 (20%)
Phase 13 (15%)
Phase 22 (10%)
Phase 31 (5%)
Phase 41 (5%)